Arkema S.A.

ENXTPA:AKE Voorraadrapport

Marktkapitalisatie: €4.6b

Arkema Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Arkema is gedaald met een gemiddeld jaarlijks percentage van -39%, terwijl de winst van de Chemicals -industrie jaarlijks groeide met 7.4%. De inkomsten zijn daalde met een gemiddeld percentage van 0.8% per jaar. Het rendement op het eigen vermogen Arkema bedraagt 0.6% en de nettomarge bedraagt 0.2%.

Belangrijke informatie

-39.02%

Groei van de winst

-38.87%

Groei van de winst per aandeel

Chemicals Groei van de industrie10.42%
Inkomstengroei-0.81%
Rendement op eigen vermogen0.56%
Nettomarge0.19%
Volgende winstupdate30 Jul 2026

Recente prestatie-updates uit het verleden

Analyseartikel • May 18

Some May Be Optimistic About Arkema's (EPA:AKE) Earnings

Soft earnings didn't appear to concern Arkema S.A.'s ( EPA:AKE ) shareholders over the last week. We think that the...
Analyseartikel • Nov 16

There May Be Reason For Hope In Arkema's (EPA:AKE) Disappointing Earnings

Arkema S.A.'s ( EPA:AKE ) stock was strong despite it releasing a soft earnings report last week. We think that...

Recent updates

Narratiefupdate • May 20

AKE: Battery Materials Expansion And Mixed Ratings Will Shape Balanced Future Prospects

Arkema's analyst price target nudged higher by about €2 to €63.88 as analysts updated their models to reflect revised assumptions for revenue growth, profit margins, discount rates and future P/E multiples following a mix of recent upgrades, downgrades and modest target increases. Analyst Commentary Recent research on Arkema presents a mixed picture, with some analysts lifting price targets or ratings and others turning more cautious.
Analyseartikel • May 18

Some May Be Optimistic About Arkema's (EPA:AKE) Earnings

Soft earnings didn't appear to concern Arkema S.A.'s ( EPA:AKE ) shareholders over the last week. We think that the...
Narratiefupdate • Apr 30

AKE: Battery Materials Expansion Will Support Future Rerating Potential

Arkema's analyst fair value estimate has moved slightly higher to about €81.56, reflecting analysts' updated assumptions on revenue growth, profit margins, and future P/E in light of recent upgrades, downgrades, and modest price target increases from several banks. Analyst Commentary Recent Street research on Arkema is mixed, but there is a clear cluster of more constructive calls that help frame how supportive analysts currently see the risk and reward around the stock.
Narratiefupdate • Apr 15

AKE: Battery Expansion And Margin Execution Will Constrain Future Re Rating Potential

Arkema's fair value estimate has shifted from €44.00 to €50.00 as analysts factor in updated assumptions on revenue growth, profit margins and future P/E multiples, in line with a recent series of higher price targets and rating changes across major research firms. Analyst Commentary Recent Street research on Arkema presents a mixed picture, with several higher price targets sitting alongside at least one downgrade and more restrained views on upside.
Narratiefupdate • Apr 01

AKE: Battery Capacity Push Will Face Execution Risk And Uncertain Earnings Trajectory

Analysts have nudged Arkema's average price target higher to around €60 to €65, citing recent target increases from several banks and mixed rating changes that reflect a more balanced view on growth, margins, and a higher assumed future P/E multiple. Analyst Commentary Recent research has given Arkema a more mixed backdrop, with some banks lifting price targets while others turn more cautious on the shares, despite keeping targets within a relatively tight €60 to €65 range.
Narratiefupdate • Mar 18

AKE: Battery Materials Expansion And Mixed Ratings Will Shape Future Rerating

Arkema's analyst price target has edged up by €0.13 to €61.88, reflecting a blend of higher fair value P/E assumptions and mixed rating actions from analysts who have recently adjusted targets between €60 and €65. Analyst Commentary Bullish Takeaways Bullish analysts are comfortable assigning price targets in the €62 to €65 range, which supports the current blended target of €61.88 and signals confidence that Arkema can justify a slightly higher P/E than previously assumed.
Narratiefupdate • Mar 04

AKE: Battery Materials Expansion And Decarbonization Efforts Will Support Future Rerating

Our analyst price target for Arkema shifts from €65.06 to €61.88 as analysts factor in recent downgrades and lower external price targets, along with updated assumptions for revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Arkema has been mixed, with both upgrades and downgrades sitting alongside reduced price targets.
Narratiefupdate • Feb 17

AKE: Battery Materials And Specialty Polymers Will Support Re Rating

Arkema's analyst price target has shifted from €85.00 to €80.00, as analysts factor in slightly softer assumptions on revenue growth, profit margins and future P/E, even as recent research updates include both an upgrade and a separate €5 adjustment to targets. Analyst Commentary Recent research on Arkema sends a mixed but broadly constructive signal, with the latest changes in price targets and ratings pointing to a more nuanced view of the company’s risk and reward profile.
Analyseartikel • Feb 13

After Leaping 26% Arkema S.A. (EPA:AKE) Shares Are Not Flying Under The Radar

The Arkema S.A. ( EPA:AKE ) share price has done very well over the last month, posting an excellent gain of 26%. Not...
Narratiefupdate • Feb 03

AKE: Battery Expansion Will Face Tougher Sector Backdrop And Execution Risk

Analysts have trimmed their price target on Arkema by €5, reflecting softer revenue growth assumptions, a slightly lower future P/E multiple, and sector headwinds highlighted in recent research, while keeping fair value broadly unchanged. Analyst Commentary Recent research points to a more cautious tone around Arkema, with pricing assumptions and sector views putting some pressure on sentiment.
Narratiefupdate • Jan 20

AKE: Battery Materials Expansion Will Face Tougher Sector Backdrop And Execution Risk

Narrative update Analysts have trimmed their price target on Arkema by €3 to €44, reflecting a lower fair value estimate along with updated views on revenue growth, margins and a reduced future P/E multiple, following recent cautious research on European chemicals and ingredients groups. Analyst Commentary Street research on Arkema has turned more cautious, with bearish analysts trimming price targets and flagging risks around growth visibility and valuation.
Narratiefupdate • Jan 06

AKE: Battery Materials Push Will Support Re Rating Despite Sector Downgrade

Analysts have trimmed their fair value estimate for Arkema to €85 from €95. This reflects lower assumed revenue growth, a slightly softer profit margin profile, a higher discount rate and more conservative future P/E expectations following recent cuts to Street price targets and a sector downgrade.
Narratiefupdate • Dec 21

AKE: Battery Materials Push Will Confront Tougher Sector Backdrop Ahead

The analyst fair value estimate for Arkema has been reduced from EUR 56 to EUR 47 as analysts factor in a higher discount rate, weaker revenue growth expectations, softer profit margins, and a sector wide shift toward more favored industrial gases and specialty distributors. Analyst Commentary Recent Street research reflects a more cautious stance on Arkema, with several bearish analysts trimming price targets and, in at least one case, reducing their rating.
Narratiefupdate • Dec 07

AKE: Sustainability And Decarbonization Investments Will Drive Future Rerating Despite Recent Downgrade

Arkema's analyst price target has been trimmed by about EUR 1 to EUR 65.06 as analysts factor in slightly softer long term growth and margin expectations, alongside a wave of recent price target cuts and a fresh Underweight rating from the Street. Analyst Commentary Recent Street research presents a mixed picture for Arkema, with several price target cuts but divergent views on the company’s medium term execution and earnings power.
Narratiefupdate • Nov 23

AKE: Recent Downgrade Will Be Offset By Sustainability Actions And Emissions Reductions

Analysts have lowered the fair value estimate for Arkema from €70.63 to €66.06, citing cautious sector sentiment and a series of reduced price targets across the chemical industry. Analyst Commentary Analysts continue to reassess Arkema's prospects in response to both company-specific and broader sector developments.
Analyseartikel • Nov 16

There May Be Reason For Hope In Arkema's (EPA:AKE) Disappointing Earnings

Arkema S.A.'s ( EPA:AKE ) stock was strong despite it releasing a soft earnings report last week. We think that...
Analyseartikel • Nov 12

Arkema S.A. (EPA:AKE) Just Reported, And Analysts Assigned A €66.94 Price Target

Investors in Arkema S.A. ( EPA:AKE ) had a good week, as its shares rose 6.6% to close at €52.60 following the release...
Narratiefupdate • Nov 06

AKE: Operational Improvements And Sustainability Efforts Will Drive Future Upside

The consensus analyst price target for Arkema has been reduced notably in recent updates, with targets now ranging from EUR 55 to EUR 80. Analysts cite cautious expectations for revenue growth and refining profit margin assumptions as reasons for the adjustment.
Narratiefupdate • Oct 23

Analysts Revise Arkema Price Target Lower Amid Cautious Optimism and Recent Sustainability Initiatives

Arkema's analyst price target has been revised downward from €72.75 to €70.63. This change reflects recent analyst adjustments driven by lower growth and profit expectations.
Narratiefupdate • Oct 09

New Capacity And R&D Focus Will Accelerate Renewable Transition

Arkema's analyst price target has been revised downward from €76.06 to €72.75. This change reflects analysts' expectations for slower revenue growth and a higher discount rate, even though profit margins have seen slight improvement.
Narratiefupdate • Sep 25

New Capacity And R&D Focus Will Accelerate Renewable Transition

Analysts have trimmed Arkema’s price target to €76.06, reflecting heightened caution around 2025 guidance cuts, persistent margin pressure, and weaker end-market demand, despite some confidence in the company’s long-term positioning. Analyst Commentary Bearish analysts cite increased risk of significant 2025 guidance cuts, particularly ahead of Q2 results.
Analyseartikel • Aug 27

Is It Too Late To Consider Buying Arkema S.A. (EPA:AKE)?

While Arkema S.A. ( EPA:AKE ) might not have the largest market cap around , it received a lot of attention from a...
Analyseartikel • Aug 06

Arkema S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Arkema S.A. ( EPA:AKE ) shareholders are probably feeling a little disappointed, since its shares fell 6.5% to €58.65...
Analyseartikel • Jul 27

These 4 Measures Indicate That Arkema (EPA:AKE) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analyseartikel • Jul 05

Potential Upside For Arkema S.A. (EPA:AKE) Not Without Risk

There wouldn't be many who think Arkema S.A.'s ( EPA:AKE ) price-to-earnings (or "P/E") ratio of 15.1x is worth a...
Analyseartikel • May 23

Arkema (EPA:AKE) Is Increasing Its Dividend To €3.60

Arkema S.A. ( EPA:AKE ) will increase its dividend from last year's comparable payment on the 28th of May to €3.60...
User avatar
Nieuw narratief • Dec 05

Specialty Materials And Renewable Energy Initiatives Ignite Earnings Growth And Margin Expansion

Strategic projects and acquisitions aim to enhance Arkema's earnings growth and stability, leveraging mega trends in energy and healthcare.

Opbrengsten en kosten

Hoe Arkema geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ENXTPA:AKE Opbrengsten, kosten en inkomsten (EUR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Mar 268,86917906284
31 Dec 259,06839923284
30 Sep 259,236127937281
30 Jun 259,443210928283
31 Mar 259,584308946280
31 Dec 249,544338935278
30 Sep 249,493346926278
30 Jun 249,425342913276
31 Mar 249,331349898274
31 Dec 239,514402892275
30 Sep 239,799393870275
30 Jun 2310,445503875273
31 Mar 2311,187752870274
31 Dec 2211,550949858270
30 Sep 2211,5431,050863264
30 Jun 2210,9691,073836257
31 Mar 2210,1801,498815248
31 Dec 219,5191,293788243
30 Sep 219,0041,212768242
30 Jun 218,5151,057755240
31 Mar 218,022350739238
31 Dec 207,884304755241
30 Sep 207,952312796242
30 Jun 208,259365815246
31 Mar 208,611422828251
31 Dec 198,738491812249
30 Sep 198,892561782245
30 Jun 198,843590766242
31 Mar 198,859633761239
31 Dec 188,816674758237
30 Sep 188,566685749235
30 Jun 188,418653743232
31 Mar 188,346594736234
31 Dec 178,326543738235
30 Sep 178,221492733233
30 Jun 178,040446728231
31 Mar 177,794433722227
31 Dec 167,535394705222
30 Sep 167,443390701220
30 Jun 167,551355701218
31 Mar 167,705341693214
31 Dec 157,683285677209
30 Sep 157,354263616194
30 Jun 156,886226555181

Kwaliteitswinsten: AKE heeft een grote eenmalige verlies van €129.1M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st March, 2026.

Groeiende winstmarge: De huidige netto winstmarges (0.2%) AKE } zijn lager dan vorig jaar (3.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van AKE is de afgelopen 5 jaar met 39% per jaar gedaald.

Versnelling van de groei: De winstgroei AKE is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: AKE had het afgelopen jaar een negatieve winstgroei ( -94.5% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Chemicals ( 6.4% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 0.6% ) van AKE wordt als laag beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/21 20:51
Aandelenkoers aan het einde van de dag2026/05/21 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Arkema S.A. wordt gevolgd door 34 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Gaurav JainBarclays
Katie RichardsBarclays
James StewartBarclays